权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Ultrabright Theranostic SERRS Nanoparticles for Gastrointestinal Endoscopy

用于胃肠内窥镜检查的超亮治疗诊断 SERRS 纳米颗粒

基本信息

批准号：
10684933
负责人：
Stephan Rogalla
金额：
$ 63.35万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-02-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10684933
关键词：
Ablation Adverse effects Animal Model Animals Biodistribution Biomedical Engineering Cancer Etiology Cancerous Cause of Death Cessation of life Chemistry Classification Clinical Clinical Trials Colon Colon Carcinoma Colonoscopy Colorectal Colorectal Cancer Crows Data Detection Doctor of Philosophy Dose Early Diagnosis Endoscopes Endoscopy Ensure Esophagus Evaluation Exclusion Experimental Designs Eye Feces Fingerprint Food Formulation Gastroenterology Gastrointestinal Endoscopy Generations Gold Grant Histologic Home Human Image Intestines Laboratories Lasers Left Lesion Lesion by Morphology Light Malignant - descriptor Malignant Neoplasms Malignant neoplasm of esophagus Malignant neoplasm of gastrointestinal tract Memorial Sloan-Kettering Cancer Center Methods Microscopic Mind Molecular Morphology Mus Nanotechnology Oncology Organ Outcome Pathology Patient-Focused Outcomes Penetration Photons Positron-Emission Tomography Precancerous Polyp Preparation Prognosis Radiology Specialty Raman Spectrum Analysis Rectal Cancer Rectum Research Signal Transduction Silicon Dioxide Specificity Stomach Surface Techniques Technology Testing Toxic effect Translating United States United States National Institutes of Health Validation Woman cancer type clinical care clinical practice clinical translation design detection limit dosage gastrointestinal imaging agent improved in vivo innovation intravenous injection malignant stomach neoplasm men meter molecular imaging nano nanoparticle novel novel strategies photothermal therapy premalignant rectal screening technology platform theranostics uptake

项目摘要

Summary Gastrointestinal cancers such as esophageal, gastric, and colorectal cancers represent some of the most challenging and lethal cancer types. Colorectal cancer alone is the third most common cause of cancer in men and women in the United States, despite implementation of colonoscopy for early detection. Esophageal and gastric cancers are less common, but their prognosis is dire if not detected early. The current standard of clinical practice uses conventional white light endoscopy, which is limited in that it offers only morphological information, has difficulties detecting microscopic lesions, and is highly operator dependent. Much greater benefits of upper and lower endoscopy would be anticipated if it would rely on specific molecular signals. To this end, we have developed a new generation of ultra-sensitive Raman nanoparticle beacons – 4th generation SERRS-Nanostars (4G Nanostars) – that after intravenous injection home specifically to both precancerous and cancerous lesions. They emit a unique Raman spectroscopic signature (“Raman fingerprint”) that clearly identifies the intestinal lesion. Because of the very high sensitivity (limit of detection in the attomolar range), even microscopic lesions of 100 µm in size can be detected. The 4G- Nanostars were developed with a special eye towards clinical translation, and consist of inert materials. Importantly, a clinical Raman endoscope that can detect the 4G-Nanostars has already been developed. We will first characterize the 4G-Nanostars with the assistance of the NIH Nanotechnology Characterization Laboratory to ensure optimal formulation and exclude any unexpected adverse effects ahead of in vivo studies. We will then determine optimal dosage in mice, and use non-invasive dynamic positron emission tomography imaging to quantify the biodistribution of 4G-Nanostars in organs and intestinal lesions. 4G-Nanostar uptake into esophageal, gastric and colonic lesions will be quantified and ranked according to the histological classification of each lesion, in order to determine if they can be used to noninvasively discriminate different lesion types. Subsequently, we will determine the accuracy with which 4G-Nanostars can detect the intestinal lesions in both mouse and large animal models of esophageal, gastric and colon cancer. We will test the accuracy of 4G-Nanostar imaging using a clinical Raman endoscope developed by our collaborators. We will also evaluate the use of SERRS-Nanostars as a theranostic agent using photothermal ablation. In summary, this proposal aims to establish a fundamentally new and highly translatable method that will allow more sensitive and specific detection and ablation of both (pre-)malignant lesions of the esophagus, stomach, colon and rectum. The experiments are designed thoroughly and rigorously so that at the end of the grant period all data has been acquired to file an IND for a clinical trial.

总结

项目成果

期刊论文数量（14）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Advances in Surface Enhanced Raman Spectroscopy for in Vivo Imaging in Oncology.

DOI：
10.7150/ntno.62970
发表时间：
2022
期刊：
Nanotheranostics
影响因子：
0
作者：
Kenry;Nicolson F;Clark L;Panikkanvalappil SR;Andreiuk B;Andreou C
通讯作者：
Andreou C

Gold/alpha-lactalbumin nanoprobes for the imaging and treatment of breast cancer.

DOI：
10.1038/s41551-020-0584-z
发表时间：
2020-07
期刊：
Nature biomedical engineering
影响因子：
28.1
作者：
Yang J;Wang T;Zhao L;Rajasekhar VK;Joshi S;Andreou C;Pal S;Hsu HT;Zhang H;Cohen IJ;Huang R;Hendrickson RC;Miele MM;Pei W;Brendel MB;Healey JH;Chiosis G;Kircher MF
通讯作者：
Kircher MF

How can we apply the use of surface-enhanced Raman scattering nanoparticles in tumor imaging?